Aethlon Medical Price to Free Cash Flow Ratio 2010-2024 | AEMD
Historical price to free cash flow ratio values for Aethlon Medical (AEMD) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Aethlon Medical Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-12-20 |
0.58 |
|
0.00 |
| 2024-09-30 |
0.47 |
$-2.23 |
0.00 |
| 2024-06-30 |
0.50 |
$-3.25 |
0.00 |
| 2024-03-31 |
1.68 |
$-4.13 |
0.00 |
| 2023-12-31 |
2.19 |
$-4.98 |
0.00 |
| 2023-09-30 |
2.26 |
$-4.68 |
0.00 |
| 2023-06-30 |
3.60 |
$-4.90 |
0.00 |
| 2023-03-31 |
3.83 |
$-5.57 |
0.00 |
| 2022-12-31 |
2.75 |
$-6.14 |
0.00 |
| 2022-09-30 |
5.82 |
$-7.32 |
0.00 |
| 2022-06-30 |
11.20 |
$-7.00 |
0.00 |
| 2022-03-31 |
14.60 |
$-6.86 |
0.00 |
| 2021-12-31 |
18.60 |
$-6.28 |
0.00 |
| 2021-09-30 |
38.60 |
$-7.10 |
0.00 |
| 2021-06-30 |
49.20 |
$-7.29 |
0.00 |
| 2021-03-31 |
20.30 |
$-8.41 |
0.00 |
| 2020-12-31 |
24.70 |
$-0.92 |
0.00 |
| 2020-06-30 |
20.30 |
$-7.00 |
0.00 |
| 2020-03-31 |
15.20 |
$-15.66 |
0.00 |
| 2019-12-31 |
9.63 |
$-46.48 |
0.00 |
| 2019-09-30 |
34.50 |
$-30.00 |
0.00 |
| 2019-06-30 |
54.75 |
$-30.10 |
0.00 |
| 2019-03-31 |
142.50 |
$-28.62 |
0.00 |
| 2020-09-30 |
13.50 |
$-1.95 |
0.00 |
| 2018-12-31 |
249.00 |
$-42.72 |
0.00 |
| 2018-09-30 |
177.00 |
$-27.86 |
0.00 |
| 2018-06-30 |
192.00 |
$-36.12 |
0.00 |
| 2018-03-31 |
178.50 |
$-47.90 |
0.00 |
| 2017-12-31 |
169.50 |
$-48.94 |
0.00 |
| 2017-09-30 |
231.00 |
$-69.17 |
0.00 |
| 2017-06-30 |
321.00 |
$-70.40 |
0.00 |
| 2017-03-31 |
489.86 |
$-68.02 |
0.00 |
| 2016-12-31 |
630.00 |
$-73.08 |
0.00 |
| 2016-09-30 |
753.00 |
$-78.02 |
0.00 |
| 2016-06-30 |
855.00 |
$-104.29 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Health Maintenance Organizations |
$0.006B |
$0.001B |
|
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
|
